Abstract：
BACKGROUND: The effect of antiplatelet and anticoagulant medications on the outcomes of sinus floor augmentation remains unclear.
METHODS: This retrospective cohort study analyzed data from electronic medical records of consecutive patients undergoing sinus floor augmentation at a single medical center. Patients were categorized into three categories: patients under antiplatelet medications, patients under anticoagulation medications, and healthy individuals. Data collected included tobacco smoking, residual alveolar bone height, timing of implant placement, materials used, vertical bone gain, early implant failure (EIF), and complications such as Schneiderian membrane perforation and postoperative bleeding. Multivariable analysis was performed to assess risk factors for EIF. Statistical significance was considered below 5%.
RESULTS: Among 110 patients with 305 implants, EIF occurred in 10% of patients and 4.65% of implants. No significant difference in postoperative bleeding or EIF was found between study groups. Univariate and multivariable analyses highlighted tobacco smoking (odds ratio [OR] = 7.92), lower residual alveolar ridge height (OR = 0.81), and staged implant placement (OR = 4.64) as significant EIF risk factors in this cohort.
CONCLUSIONS: Anticoagulant and antiplatelet therapies do not significantly elevate the risk of EIF or postoperative bleeding following sinus floor augmentation. Tobacco smoking, residual alveolar ridge height and staged sinus floor augmentation were risk factors for EIF in patients using antiplatelet or anticoagulation medications undergoing sinus floor augmentation.
METHODS: This retrospective cohort study analyzed data from electronic medical records of consecutive patients undergoing sinus floor augmentation at a single medical center. Patients were categorized into three categories: patients under antiplatelet medications, patients under anticoagulation medications, and healthy individuals. Data collected included tobacco smoking, residual alveolar bone height, timing of implant placement, materials used, vertical bone gain, early implant failure (EIF), and complications such as Schneiderian membrane perforation and postoperative bleeding. Multivariable analysis was performed to assess risk factors for EIF. Statistical significance was considered below 5%.
RESULTS: Among 110 patients with 305 implants, EIF occurred in 10% of patients and 4.65% of implants. No significant difference in postoperative bleeding or EIF was found between study groups. Univariate and multivariable analyses highlighted tobacco smoking (odds ratio [OR] = 7.92), lower residual alveolar ridge height (OR = 0.81), and staged implant placement (OR = 4.64) as significant EIF risk factors in this cohort.
CONCLUSIONS: Anticoagulant and antiplatelet therapies do not significantly elevate the risk of EIF or postoperative bleeding following sinus floor augmentation. Tobacco smoking, residual alveolar ridge height and staged sinus floor augmentation were risk factors for EIF in patients using antiplatelet or anticoagulation medications undergoing sinus floor augmentation.
摘要：
背景：抗血小板和抗凝药物对窦底扩张术结果的影响尚不清楚。
方法：这项回顾性队列研究分析了在单个医疗中心接受窦底扩张术的连续患者的电子病历数据。患者分为三类：接受抗血小板药物治疗的患者，接受抗凝药物治疗的患者，和健康的个体。收集的数据包括吸烟，残余牙槽骨高度,植入物放置的时机，使用的材料,垂直骨增益，早期植入失败（EIF），和并发症如Schneiderian膜穿孔和术后出血。进行多变量分析以评估EIF的危险因素。统计显著性被认为低于5%。
结果：在110例患者中，有305个植入物，EIF发生在10％的患者和4.65％的植入物中。研究组之间在术后出血或EIF方面没有发现显着差异。单变量和多变量分析强调吸烟(优势比[OR]=7.92)，下残余牙槽脊高度（OR=0.81），分期植入（OR=4.64）是该队列中重要的EIF危险因素。
结论：抗凝和抗血小板治疗并没有显著增加EIF或窦底扩张术后出血的风险。吸烟,在使用抗血小板或抗凝药物进行窦底扩张的患者中,残余牙槽沟高度和分期窦底扩张是发生EIF的危险因素.
方法：这项回顾性队列研究分析了在单个医疗中心接受窦底扩张术的连续患者的电子病历数据。患者分为三类：接受抗血小板药物治疗的患者，接受抗凝药物治疗的患者，和健康的个体。收集的数据包括吸烟，残余牙槽骨高度,植入物放置的时机，使用的材料,垂直骨增益，早期植入失败（EIF），和并发症如Schneiderian膜穿孔和术后出血。进行多变量分析以评估EIF的危险因素。统计显著性被认为低于5%。
结果：在110例患者中，有305个植入物，EIF发生在10％的患者和4.65％的植入物中。研究组之间在术后出血或EIF方面没有发现显着差异。单变量和多变量分析强调吸烟(优势比[OR]=7.92)，下残余牙槽脊高度（OR=0.81），分期植入（OR=4.64）是该队列中重要的EIF危险因素。
结论：抗凝和抗血小板治疗并没有显著增加EIF或窦底扩张术后出血的风险。吸烟,在使用抗血小板或抗凝药物进行窦底扩张的患者中,残余牙槽沟高度和分期窦底扩张是发生EIF的危险因素.
